Most people can relate to discomfort caused by reflux and heartburn, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events or just a cup of coffee with friends. More severe stages of GERD can be very painful, with difficulty in swallowing and esophageal erosions or ulcerations (esophagitis).
The Next Leap Forward
Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate, formerly known as X842, takes a new approach to provide improved management of GERD.
Built on world-leading industrial tradition, Linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. During 2021, clinical phase 1 trials were successfully completed and clinical phase II trials were initiated. Linaprazan glurate represents a new and novel mode of action with superior efficacy and pharmacokinetic profile versus PPI’s.
Christer Ahlberg presented at Stora Aktiedagen in Stockholm
Christer Ahlberg participated in Aktiespararnas event Stora Aktiedagen again on November 28th, this time in Stockholm. He presented Cinclus Pharma and the positive topline data released for our phase II eGERD study LEED.
Kjell Andersson - CSO and founder with decades in gastroenterology
It all started with a summer job at Astra Zeneca. Today, Kjell is one of Sweden's most experienced drug developers in acid secretion inhibition and has played an important role....
Christer Ahlberg presents Cinclus Pharma at Stora Aktiedagen
Christer Ahlberg participated in Aktiespararnas event Stora Aktiedagen in Gothenburg on November 7th. He presented Cinclus Pharma and the positive topline data released for our phase II eGERD study LEED last week.
CEO CINCLUS PHARMA